Synthesis of [ 18 F]fluoroethoxy‐benzovesamicol, a radiotracer for cholinergic neurons by Mulholland, G. Keith et al.
lonmal of lubelkd Conyrovndr and Radiophamaceuticak-Vol XXWJI, No. 7 
SYNTHESIS OF [IsFIFLUOROETHOXY -BENZOVESAMICOL, A 
RADIOTRACER FOR CHOLINERGIC NEURONS 
G. Keith Mullrolland*, Yong-Woon Jung, Donald M. Wieland, Michael R. Kilboum, 
and David E. Kuhl 
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SUMMARY 
Full experimental details are given for the preparation of [18F]fluoroethoxy- 
benzovesamicol, (-)-(2R,3R)-trans-2-hydroxy-3-(4-phenylpiperidino)-5-(2- 
[1*~fluoroethoxy)-1,2,3,4-tetralin, a new fluorine- 18 labeled cholinergic neuron 
mapping agent for use in positron emission tomography (PET). This radiotracer 
was made by nucleophilic radiofluorination of tosyloxyethoxy-benzovesamicol, 
followed by reverse phase HPLC purification, in decay corrected radiochemical 
yield exceeding 60%. 
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INTRODUCTION 
Vesamicol (AH 5183) interacts with the acetylcholine transporter protein on neuronal 
synaptic vesicles. The concmnce of [3H]vesamicol binding sites and cholinergic marker proteins 
in mammalian brains has led to the suggestion that this compound might serve as a neurochemical 
marker for cholinergic synaptic function (1-3), and created an interest in radiolabeled variants of 
vesamicol as imaging agents for in vivo mapping of cholinergic neurons (4-8). The ability to 
visualize cholinergic function could have important applications in the study of Alzheimer's disease 
and dysfunctions of the parasympathetic nervous system. A subclass of analogs discovered by 
Rogers et al., called benzovesamicols, appear to be much more potent and selective than the parent 
compound (9- 12). Several radioiodinated and carbon-1 1 labeled benzovesamicol analogs have 
been developed in our laboratories which have favorable in vivo tracer properties (3,4,13). These 
results suggest this class of compounds holds strong potential for imaging presynaptic cholinergic 
function in humans. 
FIuorine-18 ligands have a number of properties which make them of great interest as 
imaging agents. They share with "C-agents the ability for high resolution PET imaging and 
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quantification; in addition the longer 18F half life (1 10 min) allows for imaging times as late as 8 hr 
after injection, and permits multiple doses to be dispensed from a single synthesis batch. 
Furthermore, the very high specific activities (3-10 Ci/pmol) routinely attainable via "no-carrier- 
added" (nca) nucleophilic I8F labeling methods provides a greater margin of safety in comparison 
to 11C when applying toxic compounds like vesamicol as radiotracers. Several l8F-labeled 
vesamicol and benzovesamicol analogs have been investigated previously (7,14), but there 
continues to be a need for an analog with optimal tracer properties that is also easily synthesized for 
clinical investigation. 
Here is  described the preparation and chemical 
charac te r i s t ics  of  a new f luorine-  18  ana log  
fluoroethoxybenzovesamicol (FEOBV, 1) which we feel meets 
these criteria. Preliminary biological evaluation of FEOBV has 
robust tissue uptake characteristics (15). These studies are 
ongoing and full characterization of this promising agent in animals is the subject of future 
communications. 
J 3 q  A/ ph 
been encouraging in both terms of its cholinergic localization and '*F 
FEOBV (1) 
RESULTS AND DISCUSSION 
The synthetic paths for f18F]-1, authentic 1, precursors and side products are 
summarized in Scheme 1. Synthesis of the enantiomeric forms of 1 utilized the pure (-) or (+) 
isomers of 3 as starting materials, which had been resolved by the route shown in Scheme 2. 
While numerous [I8F]fluoroethyl amines and amides have been prepared for investigation 
as PET tracers (19-29). no analogous [18F]fluoroethyl ethers have been reported until very recently 
(31). The approach to [18F]-1 initially tried was adapted from the "two-step" procedure 
frequently used for labeling of N atoms with the [18F]fluoroethyl group. It involved first the 
formation of [18F]fluoroethyl tosylate (['8F]FET) from ethylene glycol ditosylate (TET) by a 
standard procedure (30), followed by in situ reaction with 4 (Scheme 1, route c.). Although the 
two-step approach did afford the desired product [18F]-1, it required the use of at least twice the 
stoichiometric amount of 4 relative to TET/[18F]FET to obtain an acceptable labeling yield of 1. 
This route was wasteful of 4, a precious chiral precursor prepared in a multistep sequence 
involving diazotization of resolved 3 (Schemes 1 and 2.). Another problem was that large 
amounts of non-radioactive side products were formed that complicated purification of [18F]-1. 
The side products were characterized in an effort to improve yields, and serendipitously, 
one of these was found to be tosyloxyethyoxybenzovesamicol2. A test labeling reaction of 2 was 
tried under standard conditions (nca [l8F]fluoride ion/K2CO3/kryptofvr in hot acetonitrile, Scheme 
1, route d.) We were pleased to find that [18F]-1 was formed as the sole radiolabeled product. 
[18F]Fluorination was fast; HPLC assay of reactions indicated labeling was complete within 3-7 
min at a heating block temperature of 120'. Compound 2 is a crystalline substance (mp 164') 
indefinitely stable under refrigemtion as the free base. It is readily obtainable on a preparative scale 
by reacting the phenoxide salt of 4 with excess TET ( Schemel. route b.). 
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Scheme 1. a. N a N e ,  H2S04; b. TBAOH, TET; c. FET, base; d. [1sF]F-/K2CO&yptofix- 
222. e. 0.2 N NaOH, 3:l:l: CH3CN:MeOH:H20 reflux. 
This combination of properties makes 2 an ideal precursor for a reliable “one-step‘’ 
synthesis of [I8F]-1. Each synthesis requires only a small quantity of 2 (0.7-1.5 mg, -1.5-3 
Fmol). Chromatographic purification of [I8F]-1 is straightforward due to the lower mobility of 
2, and the incorporation of a small C-18 extraction column and aqueous rinse cycle into the 
injection loop of the preparative HPLC simplifies sample loading and removes water soluble 
materials and kryptofix prior to HPLC injection. The average yield for the most recent 8 runs is 
61+12%, with the end-of-synthesis radioactive amounts in the range of 9-76 mCi. 
Analysis of reaction by-products indicates that oxygen nucleophiles present in the medium 
compete with fluoride ion for displacement of the tosylate function of 2 under standard labeling 
conditions. This observation has seldom been made explicitly in reported examples of N-ethyl 
tosylate radiofluorination although it undoubtedly occurs to a significant extent in those cases as 
well. Indeed, the primary (unlabeled) product in the one step labeling reaction is hydroxyethyl 
compound 5, which presumably results from attack of the tosylate by traces of OH- or C03-2 made 
soluble by the kryptofix. Deliberate hydrolysis of 2 in 3: 1: 1 CH3CNMeOH:H20 containing 0.2N 
NaOH quickly produces 5, and surprisingly, a nearly equivalent amount of methoxyethyl6 due to 
attack by methanol. These side products are of concern because of the toxicity of this general 
class of compounds (9). Formation of 5 during the labeling reaction can be lessened, though not 
avoided completely, by reducing the quantity of K2C03 to the absolute minimum- -4 pmol in our 
experience. Fortunately 5 is substantially more polar than [18F]-1, and it is efficiently removed 
during HPLC purification. 
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In conclusion, a simple and efficient synthesis of the promising new cholinergic imaging 
agent FEOBV in high purity has been developed. This method uses a stable, c h i d  precursor and 
conventional solution phase nucleophilic labeling techniques, and is amenable to large scale 
production (>50 mCi) of this agent using commercially available "black box" automated synthesis 
units with minor modifications. 
1. separation 
2. DIEAL I 
(+)-(ZS, 3S)-3 
[ a ] ~ ~ ~  = +54.1° 
Scheme 2. Resolution of enantiomers of aminobenzovesamicol3. 
EXPERIMENTAL 
1H NMR spectra were obtained in cDC13 on a Bruker 360-MHz NMR spectrometer and 
are reported in parts per million downfield from tetramethylsilane. l3C NMR spectra were 
measured at 90.56 MHz. Mass spectra were obtained in the electron impact (EI) ionization mode at 
70 eV. Molecular masses are given in atomic mass units, followed by percent intensity relative to 
the most abundant ion. Accurate mass spectral determinations were also obtained in the EI mode at 
70 eV. Elemental analyses were carried out by Spang Microanalytical Laboratory, Eagle Harbor, 
MI. Melting points were determined on a MEL-TEMP apparatus, and are uncorrected. Flash 
chromatography utilized Merck 230-400 mesh silica gel. Thin-layer chromatography (TLC) used 
Analtech 0.25 mm glass-backed plates with fluorescent indicator. Tetrabutyl ammonium 
hydroxide, (TBAOH, 1M. in methanol), ethylene glycol ditosylate and dry acetonitrile (Sure-Seal) 
were obtained from Aldrich Chemical Co. and used without further treatment. [**Fl]Fluoride ion 
was made by 17 MeV proton irradiation of [180]H20 in a silver target (16), and was either used 
directly or purifEd prior to use by a silylation procedure described previously (17). 
Resolution of (f)-5-aminobenzovesamicol, (3). 
Enantiomers of 3 were resolved by flash chromatography of the diastereomeric bis-N,O- 
(S)-(-)-a-methoxy-a-trifluoromethylphenylacetyl (MTPA) derivatives (1 8). followed by reductive 
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cleavage of the MTPA groups. To a solution of (f)-3 (9) (1.94g, 6.02 mmol), 4- 
dimethylaminopyridine (441 mg, 3.61 mmol), triethylamine (3.36 mL, 24.1 mmol) in dry CHC13 
(15 mL) was added dropwise via syringe (S)-(-)-MTPA chloride (3.49g, 13.84 mmol) at room 
temperature. The resulting solution was stirred for 6 hours and then poured into ethyl acetate (30 
mL). The solution was washed with saturated NaHC03 solution (30 mL) and the aqueous layers 
were extracted with ethyl acetate (2 x 30 mL). The combined extracts were dried over anhydrous 
Na2S04 and concentrated under reduced pressure. The two diastereomeric N,O-bis-MTPA 
isomers were separated by flash column chromatography on silica using EtOAc: CH2C12: hexane 
1:2:7. The less polar compound (Rfa.25,  EtOAc: CH2C12: hexane 1:2:7, silica gel) was (+)- 
(S,S)-bis-MTPA-diastereoisomer. It was isolated in 99% yield (2.25g). The more polar 
compound (Rf=0.14, 1:2:7 EtOAc: CH2C12 :hexane, silica gel), was the (-)-(R,R)- 
diastereoisomer. It was obtained in a yield of 2.238 (98%). 
The (-)-(R,R)-bis-MTPA-diastereoisomer (2.20g, 2.92 mmol) was dissolved in dry 
toluene (30 mL) and cooled to -78OC. Diisobutyl aluminum hydride (1 1.7 mL of 1.0 M solution 
in cyclohexane, 11.7 mmol) was added dropwise via syringe. The resulting solution was stirred at 
-78oC for 30 min. and allowed to warm to room temperature. The reaction was quenched with 2.5 
N HCl (30 mL). The aqueous layers were separated, made alkaline (pH=lO) with 3.0 N NaOH 
solution and extracted with CH2C12 (3 x 50 mL). The organic extracts were dried over anhydrous 
Na2S04 and concentrated under reduced pressure. The residue was flash-chromatographed on 
silica gel with 50% EtOAc in hexane to afford 880 mg (94%) of (-)-(R,R)-3 ( [ a ] ~ 2 3 =  -58.1, 
C=1.5, EtOH). (+)-(R,R)-3 was obtained in 90% yield from the (+)-bis)-MTPA diastereomer 
using the same procedure as above ( [ a ] ~ 2 3 =  +54.7, C=1.5, EtOH). Enatiomeric purities of (-)- 
and (+)-enantiomers were 9 9 %  as determined by chiral HPLC using a Chiracel OD column (4.6 x 
250 mm) with a 2-propanoVhexaneE~NH (5050: 1) mobile phase at a flow rate of 1 mUmin and 
UV detection at 254 mm. Retention times of (+)- and (-)-3 enantiomers were 8.25 and 9.44 min, 
respectively. 
(-)-(2R,3R)-Trans--2-hydroxy-3-(4-phenylpiperidino)-5-hydroxytetralin, (-)-5- 
hydroxybenzovesamicol, (-)HOBV, (4). 
Diazotization of (-)-3. To a solution of concentrated sulfuric acid (2 mL) and water (4 mL) 
was added a solution of (-)-3 (150 mg, 465 p o l )  in THF (3 mL). The resulting solution was 
cooled to 5oC and a solution of sodium nitrite (38.5 mg, 558 vmol) in water was added dropwise 
while the temperature of the solution was maintained below 7oC. The diazonium solution was 
stirred for 1 hour and added dropwise to a second solution of H2SO4 (2 mL) and water (10 mL) 
which was heated to boiling. The mixture was boiled for 5 min after the additions were completed 
and then allowed to cool to room temperature. The solution was brought to pH 9 with 10 N NaOH 
solution and extracted with ethyl acetate (3x40 mL). The combined extracts were dried over 
anhydrous N a 2 S 0 4  and concentrated under reduced pressure. The residue was flash- 
chromatographed on silica with 30% ethylacetate in hexane to afford (-)-4 after evaporation, as a 
tan solid, mp 216'. (68 mg, 45%). 1H NMR (CDC13): 6 1.71-1.95(m, 4H), 2.43-2.65(m, 3H), 
2.78-3.08(m, 6H), 3.30(dd, J=16.1, 5.6 Hz, lH), 3.99(ddd, J=16.1, 10.4, 5.6 Hz, 1H) 
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5.03(br.s, OH), 6.62(d, J=7.9 Hz, lH), 6.71(d, J=7.6 Hz, lH), 7.02(t, J=7.8 Hz, lH), 7.19- 
7.35 (m, 5H) ppm; 13C NMR (CDC13): 6 19.97, 33.92, 34.40, 37.93, 42.95, 45.00, 53.58, 
65.49, 66.56, 112.15, 121.52, 121.93, 126.23, 126.82, 126.89, 128.46, 135.85, 146.09, 
153.72 ppm; MS (EI, 70 eV) mlz (relative intensity) 323(61.54, M+), 306(4.31), 174(100.00), 
162(26.25), 160(24.67), 145( 12.19). 131(13.32); High Resolution MS (EI, 70 eV): Calcd. for 
C21H25N02 323.1885, Found 323.1892; Anal. Calcd for C21H25N02: C,77.99; H,7.79; 
N,4.33. Found: C.77.81; H,7.74; N,4.36. The (+) isomer of 4 was prepared similarly from 
(+)-3 in 40% yield. It had identical analytical data to (-)-4, including melting point. Racemic 4 
had a mp of 208-210OC. 
(-)-(2R,3R)-trans--2-hydroxy-3-(4-phenylpiperidino)-5-(2-tosyloxethoxy)- 
tetralin, (-)-5-(2-tosyloxyethoxy)-benzovesamicol, (-)TEOBV, (2). 
A solution of (-)-HOBV 4 (5 mg, 15.5 pnol) and TBAOH (17 pnol, 17 WL of a 1 M 
solution in MeOH) in 2 mL of acetonitrile was evaporated to dryness on a rotary evaporator at 
room temperature, and then dry acetonitrile (1mL ) was added to the residue and the mixture was 
re-evaporated to remove traces of moisture. Ethylene glycol ditosylate (74 mg, 200pmol) and 2 
mL of acetonitrile were added to the residue and and the reaction mixture was warmed at 60-70' for 
2 hr, or untildl HOBV had disappeared, as measured by analytical reverse phase HPLC (column: 
5 micron silica C-18, mobile phase: 1.5 mumin, 3: 1: 1 CH3CN MeOH: 20 mM KHPO4, pH 
6.7; ~ H O B V  1.6, ~ ' F E O B V  3.25, k'TEOBV 6.4). The product 2 was isolated by flash 
chromatography on silica using a hexane: Et2O step gradient to give, after crystallization from 
iPrOH, 5.6 mg (69%) of white crystals of (-)TEOBV 2, mp 164-166OC. The (+) isomer was 
prepared in identical fashion from (+)HOBV. It had a melting point of 165- 166'. Racemic 2 had a 
melting point of 157OC. 1H NMR (CDC13): 6 1.65-1.97(m, 4H), 2.45(s, 3H), 2.48-2.68(m, 
3H), 2.75-3.09(m,6H), 3.28(dd, J=15.9, 5.6 Hz, lH), 3.85(td, J=10.2, 5.6 Hz, lH), 4.18(td, 
J=4.7, 2.3 Hz, 2H), 4.41(t, J =4.7 Hz, 2H), 6.56(d, J=7.8 Hz, lH), 6.75(d, J=7.8 Hz, lH), 
7.07(t, J=7.8 Hz, lH), 7.16-7.36(m, 7H), 7.82(d, J=8.4 Hz, 2H) ppm.; MS (EI, 70eV): 
m/z(relative intensity) 521(M+, 26. l), 385(20.4), 372(8.0), 350(48.4), 323(9.2), 279(5.3), 
213(5.7), 212(3.8), 203(5.2), 199(12.2), 174(50.6), 167(10.7), 160(11.6), 149(27.7), 57(100); 
High Resolution MS (EI 70 eV): Calcd. for C30H35NOgS 521.2236, found: 521.2245; Anal. 
calcd for C30H35NOgS: C,69.07; H,6.76; N, 2.68. Found: C, 69.25; H, 6.69; N, 2.60. 
(-)-(2R,3R)-Trans--2-hydroxy-3-(4-phenylpiperidino)-5-(2-fluoroethoxy)- 
tetralin, (-)-5-(2-fluoroethoxy)-benzovesamicol, FEOBV, (1). 
A solution of (-)-HOBV 4 (60 mg, 186 pmol) was dissolved in 3 mL of CH2C12 under 
inert atmosphere and 200 pL of 1 M TBAOH in MeOH was added. The solvent was removed by 
rotary evaporation at room temperature. To the residue was added 2mL of dry CH3CN which was 
then evaporated to azeotropically remove traces of moisture. This step was repeated once, The 
residue containing the dark phenoxide salt was resuspended in a fresh 3.5 mL portion of CH3CN 
and 2-fluoroethyl tosylate (50 mg, 230 pnol) was added. The mixture was heated (inert 
amnosphere) at 70-80' for 2 hr, or until the the consumption of HOBV was complete, as measured 
by HPLC. Following evaporation of reaction solvent, the crude product was partitoned between 
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CH2C12 and water, and the CH2C12 layer was washed with 0.5N NaOH, dried (Na2S04), and 
concentrated to an oil, which was purified by flash chromatography (hexane:EtOAc). The yield of 
final product (-)-l (white crystals, mp 149-150°, from MeOH) was 53 mg (77%). 1H NMR 
(CDC13): 6 1.72-1.94(m, 4H), 2.46-2.65(m, 3H), 2.74-3.02(m, 5H), 3.10(dd, J=16.7, 5.0 Hz, 
1H). 3.29(dd, J=16.1, 5.6 Hz, lH), 3.86(td, J=10.5, 5.6 Hz.lH), 4.23(dtd, JH-F=28.0, 4.1, 
1.8 Hz, 2H), 4.79(dt, JH-Fd7.3, 4.1 Hz, 2H), 6.65(d, J=7.9 Hz, lH), 6.77(d, J=7.9 Hz, lH), 
7.11(t, J=7.9 Hz, lH), 7.18-7.35(mSH) ppm.; MS (EI, 70eV) m/z (relative intensity) 369(M+, 
26.14), 322(2.99), 219(6.56), 208(3.27), 203(7.53), 202(7.88), 191(7.21), 186(4.46), 
179(5.82), 174( lOO.OO), 172(20.95), 162( 15.58), 160(17.47), 146(8.39), 131(19.55), 
115(22.00), 103(15.90), gl(31.74); High Resolution MS (EI 70 eV): Calcd. for C23H28FN02 
369.2104, Found 369.2101; Anal. calcd. for C23H28FN02: C,74.77; H,7.64; N, 3.79. Found: 
C, 74.79; H, 7.60; N, 3.90. 
(-)-(2R,3R)-Trans--2-hydroxy-3-(4-phenylpiperidino)-5-(2-[ 18F]fluoroethoxy)- 
tetralin, (-)-5-(2-[18F]fluoroethoxy)-benz~vesamicol, [18F]FEOBV, ([18F]-1). 
To an azeotropically dried CH3CN solution of nca [18F]fluoride ion, K2CO3 ( 1.04 mg, 
7.5 pmol). and kryptofix 222 (6 mg, 16 pmol) was added 2 (0.7-1.5 mg, 1.5-3 pmol). The 
mixture (1 mL total solution volume) was heated at 110-120' for 6-10 min in a septum-sealed, 
magnetically stirred pyrex "V-vial". The reaction solution was diluted 1:l with water and passed 
through a C-18 silica (Fisher, 150 mg) solid-phase extraction column mounted on a HPLC 
injection valve in the "Load" position. The cartridge was washed with water (3 x 1 mL) and then 
was switched to the "Inject" position to elute the retained crude [18F]-1 with HPLC solvent onto 
a preparative HPLC column for purification. Conditions: C-18 10 micron, 10 x 250 mm column; 
mobile phase 65: 15: 25 CH3CN: MeOH: 10 mM KHPO4, pH 6.7,4 mumin. [18F]-1 eluted at 
12-13.5 min. separated from 2 (18 min), and a non-radioactive polar material ( Rt 6-8 min, 
compound 5, see below). After adding 2 drops of glacial acetic acid to the product fraction, the 
solvent was removed by rotary evaporation at 60'C. The final product [l8F]-l was formulated in 
saline containing 2.5% ethanol for intravascular injection. The specific activity exceeded 2000 
CUmmol with 99% radiochemical purity at end of synthesis, as indicated by analytical reverse 
phase HPLC (column: 5 micron C-18 silica, mobile phase: 1.5 mumin, 3: 1: 1 CH3CN MeOH: 
20 mM KHP04, pH 6.7, with serial UV 220 nm and gamma radioactivity (CaF2) detectors); 
k'mOBv 3.25, k'TEOBV 6.4., k'5 1.45. The apparent lower limit for quantification of 1 under 
routine conditions was 500 ng/mL of formulated solution. The overall time of synthesis beginning 
with [ 18F]fluoride solution was 50-70 min and the decay corrected yields ranged from 44-81%. 
The polar non-radioactive by-product 5 (prep HPLC retention 6-8 min, analytical HPLC 
k'= 1.45) was isolated from pooled labeling reactions, and identified as (-)-(2R,3R)-trans--2- 
hydroxy-3-(4-phenylpiperidino)-5-(2-hydroxyethoxy)-tetralin, (-)-5-(2-hydroxy- 
ethoxy)-benzovesamicol, on the basis of mass spectral analysis. MS (EI, 70 eV). m/z 
(relative intensity): 367( 100, M+). 350( 10, M-OH), 323( 12), 322(14, M-CH2CH20H), 315(20), 
301(23), 227(14), 217(16), 175(10), 174(44), 172(12), 160(1 l), 149(20), 144(12), 114(12), 
71(15), 57(22), 56(15), 55(11.8) 45(16), 43(18 ), 41(12). High Resolution MS (EI 70 eV): 
Calcd. for C23H2gN03 367.2147, Found 367.2135. The same material was produced when 2 
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(-lmg, 2 pmol) was refluxed 0.2 N NaOH in 3:l:l CH3CN:MeOH:HzO. Complete 
disappearance of 2 occured in 40 min. 
A second, less polar compound was also formed from 2 under these test solvolysis 
conditions, in yield equivalent, by UV detector integration, to the amount of 5 produced. The 
amount of this second product isolated by HPLC was sufficient only for characterization by MS. 
(EI, 7OeV) mlz(re1ative intensity): 381(100, M+), 350(20), 323(20), 322( 19), 227(25), 200(25), 
174(63), 133(22) 89(40), 69(20), 59(27), 45(75). Accurate mass for molecular ion (38 1.2326) 
gave a formula of C ~ H 3 1 N 0 3  (predicted: 381.2304) which corresponds to replacement of the 
tosylate group in 2 with a methoxy group. The assigned structure was (-)-(2R,3R)-trans--2- 
hydroxy-3-(4-phenylpiperidino)-5-(2-methoxyethoxy)-tetralin, (-)-5-(2-methoxy- 
ethoxy)-benzovesamicol, (6). 
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